Saman Nematollahi

Dr. Saman Nematollahi


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Journal of Public Health
Verified
Journal Article
Closed access
RHRyoko Hamaguchi
Ryoko Hamaguchi
SNSaman Nematollahi
Saman Nematollahi
DMDaniel J Minter
Daniel J Minter
As a global crisis, COVID-19 has underscored the challenge of disseminating evidence-based public health recommendations amidst a rapidly evolving, often uncensored information ecosystem—one fueled in part by an unprecedented degree of connected afforded through social media. In this piece, we explore an underdiscussed intersection between the visual arts and public health, focusing on the use of validated infographics and other forms of visual communication to rapidly disseminate accurate public health information during the COVID-19 pandemic. We illustrate our arguments through our own experience in creating a validated infographic for patients, now disseminated through social media and other outlets across the world in nearly 20 translations. Visual communication offers a creative and practical medium to bridge critical health literacy gaps, empower diverse patient communities through evidence-based information and facilitate public health advocacy during this pandemic and the ‘new normal’ that lies ahead.

29 August 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SNSaman Nematollahi
Saman Nematollahi
Nitipong PermpalungNitipong Permpalung
Nitipong Permpalung
SZSean Zhang
Sean Zhang
MMMegan Morales
Megan Morales
KMKieren A Marr
Kieren A Marr
Aspergillus lentulus is a drug-resistant species that is phenotypically similar to A. fumigatus. It was discovered as a cause of azole-breakthrough disease, consistent with in vitro resistance. Clinical labs can misidentify the species as fumigatus based on phenotypic typing. We describe 4 recent cases and provide a brief review.

14 October 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
NCNipat Chuleerarux
Nipat Chuleerarux
KMKasama Manothummetha
Kasama Manothummetha
CMChatphatai Moonla
Chatphatai Moonla
ASAnawin Sanguankeo
Anawin Sanguankeo
OKOlivia S. Kates
Olivia S. Kates
Nitipong PermpalungNitipong Permpalung
Nitipong Permpalung
Patients with multiple myeloma (MM) have a diminished immune response to coronavirus disease 2019 (COVID-19) vaccines. Risk factors for an impaired immune response are yet to be determined. We aimed to summarize the COVID-19 vaccine immunogenicity and to identify factors that influence the humoral immune response in patients with MM. Two reviewers independently conducted a literature search in MEDLINE, Embase, ISI Web of Science, Cochrane library, and Clinicaltrials.gov from existence until 24 May 24 2022. (PROSPERO: CRD42021277005). A total of 15 studies were included in the systematic review and 5 were included in the meta-analysis. The average rate (range) of positive functional T-lymphocyte response was 44.2% (34.2%-48.5%) after 2 doses of messenger RNA (mRNA) COVID-19 vaccines. The average antispike antibody response rates (range) were 42.7% (20.8%-88.5%) and 78.2% (55.8%-94.2%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. The average neutralizing antibody response rates (range) were 25% (1 study) and 62.7% (53.3%-68.6%) after 1 and 2 doses of mRNA COVID-19 vaccines, respectively. Patients with high-risk cytogenetics or receiving anti-CD38 therapy were less likely to have a humoral immune response with pooled odds ratios of 0.36 (95% confidence interval [95% CI], 0.18, 0.69), I2 = 0% and 0.42 (95% CI, 0.22, 0.79), I2 = 14%, respectively. Patients who were not on active MM treatment were more likely to respond with pooled odds ratio of 2.42 (95% CI, 1.10, 5.33), I2 = 7%. Patients with MM had low rates of humoral and cellular immune responses to the mRNA COVID-19 vaccines. Further studies are needed to determine the optimal doses of vaccines and evaluate the use of monoclonal antibodies for pre-exposure prophylaxis in this population.

15 May 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
SNSaman Nematollahi
Saman Nematollahi
DMDaniel J Minter
Daniel J Minter
BBBrooke Barlow
Brooke Barlow
NNNathanial S Nolan
Nathanial S Nolan
JSJennifer O Spicer
Jennifer O Spicer
GEGerome V Escota
Gerome V Escota
Social media (SoMe) platforms have been increasingly used by infectious diseases (ID) learners and educators in recent years. This trend has only accelerated with the changes brought to our educational spaces by the coronavirus disease 2019 pandemic. Given the increasingly diverse SoMe landscape, educators may find themselves struggling with how to effectively use these tools. In this Viewpoint we describe how to use SoMe platforms (e.g., Twitter, podcasts, and open-access online content portals) in medical education, highlight medical education theories supporting their use, and discuss how educators can engage with these learning tools effectively. We focus on how these platforms harness key principles of adult learning and provide a guide for educators in the effective use of SoMe tools in educating ID learners. Finally, we suggest how to effectively interact with and leverage these increasingly important digital platforms.

8 October 2024 in Mycoses
Verified
Journal Article
Closed access
KSKaran Srisurapanont
Karan Srisurapanont
BLBhoowit Lerttiendamrong
Bhoowit Lerttiendamrong
TMTanaporn Meejun
Tanaporn Meejun
JTJaedvara Thanakitcharu
Jaedvara Thanakitcharu
KMKasama Manothummetha
Kasama Manothummetha
Nitipong PermpalungNitipong Permpalung
Nitipong Permpalung

23 April 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
NCNipat Chuleerarux
Nipat Chuleerarux
ATAchitpol Thongkam
Achitpol Thongkam
KMKasama Manothummetha
Kasama Manothummetha
SNSaman Nematollahi
Saman Nematollahi
VDVeronica Dioverti-Prono
Veronica Dioverti-Prono
Nitipong PermpalungNitipong Permpalung
Nitipong Permpalung
Background: Cytomegalovirus (CMV) and invasive aspergillosis (IA) cause high morbidity and mortality in solid organ transplant (SOT) recipients. There are conflicting data with respect to the impact of CMV on IA development in SOT recipients. Methods: A literature search was conducted from existence through to 2 April 2021 using MEDLINE, Embase, and ISI Web of Science databases. This review contained observational studies including cross-sectional, prospective cohort, retrospective cohort, and case-control studies that reported SOT recipients with post-transplant CMV (exposure) and without post-transplant CMV (non-exposure) who developed or did not develop subsequent IA. A random-effects model was used to calculate the pooled effect estimate. Results: A total of 16 studies were included for systematic review and meta-analysis. There were 5437 SOT patients included in the study, with 449 SOT recipients developing post-transplant IA. Post-transplant CMV significantly increased the risk of subsequent IA with pORs of 3.31 (2.34, 4.69), I2 = 30%. Subgroup analyses showed that CMV increased the risk of IA development regardless of the study period (before and after 2003), types of organ transplantation (intra-thoracic and intra-abdominal transplantation), and timing after transplant (early vs. late IA development). Further analyses by CMV definitions showed CMV disease/syndrome increased the risk of IA development, but asymptomatic CMV viremia/infection did not increase the risk of IA. Conclusions: Post-transplant CMV, particularly CMV disease/syndrome, significantly increased the risks of IA, which highlights the importance of CMV prevention strategies in SOT recipients. Further studies are needed to understand the impact of programmatic fungal surveillance or antifungal prophylaxis to prevent this fungal-after-viral phenomenon.